Jim Januzzi, MD, Director, Dennis and Marilyn Barry Fellowship in Cardiology Research, Massachusetts General Hospital Cardiology Division speaks about American College of Cardiology studies will explore whether AI can improve clinicians' guideline adherence.
Link to Article:
The American College of Cardiology (ACC) is preparing three trials to see if customized clinical guideline assistance given at the point of treatment by an AI tool may enhance cardiac patient outcomes.
HealthReveal's software will be used in each of the TRANSFORM trials to develop and give care recommendations based on current best practices. The electronic health record (EHR) system provides doctors with these insights, which include medical literature that informs the software's suggestions.
The research is part of ACC's TRANSFORM project, which began in 2019 and is a new type of quality research program. The pharmaceutical and medical device industries, health plans, employers, doctors, and patients are all involved in these initiatives, which use EHR data, office-based treatments, and collaborations.
In order to fuel the study, ACC teamed with Veradigm, a health information technology firm owned by Allscripts, to build clinical quality improvement and research networks as part of the TRANSFORM initiative. The Pinnacle Registry, which focuses on coronary artery disease, hypertension, heart failure, atrial fibrillation, and diabetes in outpatient settings, and the Diabetes Collaborative Registry are both owned and operated by Veradigm.
These outpatient registries are used by all of the TRANSFORM programs to assist identify providers and patients who are qualified to participate in the program.
The TRANSFORM HFrEF research will be the ACC's first study as part of its collaboration with HealthReveal. It will be directed by Jim Januzzi, M.D., a cardiology researcher at Massachusetts General Hospital, and will focus on the management of patients with heart failure and a low ejection fraction (HFrEF).
Effective treatment techniques have already been discovered, according to Januzzi, who is also a trustee of the ACC and a professor of medicine at Harvard Medical School.
According to 2018 research, fewer than a quarter of HFrEF patients got medication therapies as indicated by current clinical recommendations, and less than 1% of those prescriptions were filled at the correct dosage. Patient outcomes may be deteriorated as a result of noncompliance, as well as greater expenditures for extra care.
The clinical AI software's merits, according to Januzzi and Lonny Reisman, M.D., founder, and CEO of HealthReveal, are its scalability and capacity to update suggestions during the course of therapy. According to Reisman, the tool is also transparent about how it comes to its findings, which is crucial for winning doctors' trust and ensuring that care follows the guidelines.